Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Exenatide is used for type 2 diabetes treatment to improve glycemic control and modestly reduce body weight through GLP-1–like insulinotropic and glucagonostatic effects6768, PEG-MGF is used experimentally to enhance muscle repair and hypertrophy after mechanical overload or injury by stimulating satellite-cell activation and protein synthesis6373138.
While Exenatide works as a 39-amino-acid exendin-4 peptide originally isolated from Gila monster venom that acts as a long-acting GLP-1 receptor agonist resistant to DPP-4 degradation67, PEG-MGF is a poly(ethylene glycol)-conjugated form of Mechano Growth Factor (IGF-1Ec splice variant) comprising the 24-aa C-terminal E-peptide of IGF-1, designed to extend half-life while activating IGF-1 receptor–mediated anabolic signaling in muscle satellite cells637322138.
Exenatide
Not assigned in the current dataset.
PEG-MGF
IGF1
Exenatide and PEG-MGF are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Exenatide is more often discussed in the realm of Metabolic and endocrine, whereas PEG-MGF is more often associated with the realm of Musculoskeletal health and Cardiovascular health. Their biological logic is quite different: Exenatide is a receptor agonist, whereas PEG-MGF is a growth factor mimetic and a signaling modulator. Exenatide has a more venom-derived origin, while PEG-MGF is closer to synthetic analog background and their development context also differs, with Exenatide approved while PEG-MGF is in Preclinical development. Exenatide takes the form of a linear peptide, whereas PEG-MGF is closer to a peptide conjugate, Exenatide carries amidation features, while PEG-MGF instead reflects pegylation changes; while their sequence patterns also diverge, with Exenatide showing alpha-helical domain features and PEG-MGF showing protein-mimetic sequence features.